Summit Therapeutics Inc. (SMMT): R&D Expense
$537.67M
Year ended 2025-12-31
$568.74M
Trailing 12 months to 2026-06-30
+117.9%
3-year compound annual growth
+58.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $537.67M | +256.6% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $150.78M | +153.5% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $59.47M | +14.4% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $52.00M | -39.1% | 2025-02-24, From 2022-01-01 |
| 2021-12-31 | $85.35M | +60.2% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $53.27M | n/a | 2022-12-21, From 2020-01-01 |
| No annual figure between 2019-01-31 and 2020-12-31. | |||
| 2019-01-31 | $52.00M | n/a | 2021-03-31, From 2018-02-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $537.67M | +256.6% |
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $32.51M | +56.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $215.26M | +70.6% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $17.40M | -9.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $173.14M | -14.2% |
Compare SMMT, AUPH, KNSA, KURA side by side · Screen every company in Pharmaceutical Preparations ↗